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cooked pork is a diet staple, underdi-
agnosis of S. suis infection is likely. 
Greater understanding of this organ-
ism and its disease spectrum would 
promote earlier diagnosis and preven-
tion of sequelae. 
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Parvoviruses in 
Blood Donors and 
Transplant 
Patients, Italy
To the Editor: Parvoviruses 
(PARV) 4 and 5 are 2 genotypes of 
a novel human parvovirus, with 92% 
nucleotide identity, identifi ed in the 
plasma sample of a patient screened 
for acute HIV infection and in samples 
of manufactured plasma pools (1,2). 
Recently, PARV4 and PARV5 were 
identifi ed in blood samples from 3 of 
26 cadavers from the United Kingdom, 
all of whom were positive for hepatitis 
C virus RNA and had a history of in-
travenous drug use (3). PARV4/5 were 
also found in bone marrow (BM) and 
lymphoid tissues from 17 of 24 HIV-
positive cadavers from Scotland (4) 
and in BM aspirates from 16 of 35 Ital-
ian patients with AIDS (5). Little or no 
information is available about the epi-
demiology and clinical correlates of 
infection with these novel viruses. To 
provide insights into their pathogenic 
potential in vivo, we assessed the fre-
quency of PARV4/5 viremia in healthy 
patients, transplant patients, and those 
with suspected viral disease. 
We performed a retrospective 
molecular study for the presence of 
PARV4/5 sequences in 4 groups of 
417 Italian HIV-negative persons. 
Group 1 consisted of 100 blood donors 
recruited from the Transfusion Centre 
of Modena (northern Italy); group 2, 
84 patients with hematologic diseases 
showing clinical signs of viral etiol-
ogy but negative results for the most 
common viruses (herpesviruses, ade-
novirus, hepatitis virus, and coxsackie 
virus). For both of these groups, DNA 
was extracted for analysis from se-
rum specimens and peripheral blood 
mononuclear cells (PBMCs). Groups 
3 and 4 comprised recipients of kid-
ney and allogeneic BM/peripheral 
blood stem cell (PBSC) transplants, 
for which DNA was extracted from 
serum specimens collected at 6 and 
12 months, respectively, after trans-
plantation. The nested PCR method 
was used to amplify a shared sequence 
of PARV4 and its variant PARV5 
and was specifi c for the open read-
ing frame 1. First step PCR was per-
formed as previously described (2) 
with a sensitivity of 1–10 copies, on 
1 μg PBMC DNA and on one fi fth of 
DNA extracted from 0.25 mL of serum. 
Primers for second round PCR were 
PV4NS1Fn2 (5′-GTTGATGGYCCT-
GTGGTTAG-3′) and PV4NS1Rn2 
(5 ′-CCTTTCATATTCAGTTCCT-
GTTCAC-3′). All positive results were 
confi rmed by direct sequencing.
We found 3 positive case-patients, 
including 2 renal transplant recipients 
and 1 patient with a suspected viral 
disease; none of the blood donors test-
ed positive on single-round PCR. On 
nested PCR, 1 blood donor had posi-
tive results; the positivity rate did not 
increase in the other groups (Table). In 
the fi rst 2 groups, PARV4/5 sequences 
were detected only in the serum sam-
ples, not in the PBMCs collected at the 
same time. These sequences suggest 
that PBMCs are not a major site of 
viral replication. Similar to B19 infec-
tion, which is rarely reactivated in the 
setting of BM/PBSC transplantation 
(6,7), none of the BM/PBSC trans-
plant patients were PARV4/5 positive. 
The detection of PARV4/5 sequences 
in the serum collected at 12 months 
after transplantation was not associ-
ated with the occurrence of any symp-
toms in the 2 renal recipients. Of note, 
the available serum samples collected 
from both recipients before transplan-
tation, and at 6 and 24 months after 
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transplantation, were PARV4/5 nega-
tive, which suggests that asymptomat-
ic PARV4/5 infection may transiently 
occur after solid organ transplantation 
or may be acquired throughout trans-
fusion or transplantation. Similarly, 
the rate of B19 infection in solid organ 
transplant recipients is low (1.4%–
1.8%), and most B19 DNA–positive 
patients remain asymptomatic (8,9).
PARV4/5 sequences were detected 
in the serum collected from 1 patient 
affected with Wegener granulomato-
sis. This patient was under long-term 
treatment with steroids, concomitant 
with the development of a clinical 
syndrome for which a viral cause was 
suspected, including fever, severe ane-
mia, a histologic-examination–proven 
postinfectious glomerulonephritis, and 
eryhtroid hypoplasia, with dsyseryth-
ropoiesis and dismegakaryopoiesis 
on BM examination. Serologic and 
molecular tests for the most common 
viruses, including B19, were negative 
and the patient died of multiple organ 
failure 1 month later. Single-cell PCR 
performed on the DNA extracted from 
isolated BM erythroid and myeloid 
progenitors in the formalin-fi xed, 
paraffi n-embedded BM tissue biopsy 
specimens, collected 2 days before 
death and at autopsy, were PARV4/5 
negative. While the PARV4/5 viremia, 
in the absence of other known viral 
agents, suggests a possible contribu-
tion of this novel parvovirus to the pa-
tient’s clinical syndrome, the absence 
of the virus in the BM cells suggests 
that its in vivo tropism may markedly 
differ from that of B19.
In conclusion, although the fre-
quency of PARV4/5 viremia is very 
low in the general Italian population, it 
is slightly higher in certain subgroups 
of iatrogenically immunosuppressed 
patients and it is not clear to which 
extent immunosuppression enhances 
viral reactivation and/or primary in-
fection. Failure to detect PARV4/5 
DNA in all but 4 study patients does 
not necessarily indicate a rarity of past 
viral exposure or infection in trans-
plant patients or indeed in the general 
population. Further studies are needed 
to confi rm a possible pathogenic role 
of PARV4/5 infection. 
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Table. Analysis of 417 patients tested for parvoviruses 4/5 by PCR* 
No. cases positive on serum samples/  
no. tested (%) 
No. cases positive on PBMCs/
no. tested 
Group First-round PCR Nested PCR First-round PCR Nested PCR 
Blood donors 0/100 1/100 (1) 0/100 0/100
Patients with suspected viral diseases 1/84 (1.2) 1/84 0/84 0/84
BM/PBSC transplant recipients 0/107 0/107 ND ND
Kidney transplant recipients (%) 2/126 (1.6) 2/126 ND ND
*PBMCs, peripheral blood mononuclear cells; BM, bone marrow; PBSC, peripheral blood stem cell; ND, not done.                 
1These authors contributed equally to the 
study.
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Antimicrobial Drug 
Use and Antibiotic-
Resistant Bacteria
To the Editor: The article by Har-
ris et al., published in the August 2007 
issue of Emerging Infectious Diseases, 
examined the risk factors for selecting 
extended-spectrum β-lactamase–pro-
ducing Enterobacteriaceae in inten-
sive-care patients and found that ex-
posure to piperacillin/tazobactam and 
vancomycin were independent risk 
factors (1). Although antimicrobial 
drug use has been historically linked 
to antibiotic resistance in bacteria, we 
should not miss the perspective that 
such a risk factor mostly favors the 
cross-transmission of preexisting an-
tibiotic-resistant bacteria, taking into 
account the disruption of the endog-
enous microfl ora, rather than the se-
lection of “de novo” resistant mutants 
(2). This supposition is supported by 
many articles that have found genetic 
similarity between antibiotic-resistant 
microorganisms that occur in hospi-
talized patients, as well as by the fact 
that most of these pathogens exhibit 
cross-resistance with different classes 
of drugs, which should be extremely 
rare on a mutation basis. 
This hypothesis is also supported 
by the evidence that healthcare work-
ers frequently do not obey simple 
infection control precautions such 
as practicing hand hygiene between 
contact with different patients (3–6). 
That is likely why Larson et al., in a 
multicenter study in the United States, 
recently found no relationship be-
tween antimicrobial drug control poli-
cies and level of antibiotic resistance 
in bacteria, but did fi nd an association 
between lower levels of antibiotic re-
sistance in Staphylococcus aureus and 
enterococci and high compliance with 
hand hygiene (7).
Therefore, perhaps we should start 
looking for risk factors for being colo-
nized or infected by any antimicrobial 
drug–resistant bacterium, including 
in our analysis some infection control 
measures adopted commonly during 
outbreak investigations, such as expo-
sure to doctor A or nurse B, proximity 
to a known colonized patient, under-
staffi ng during the period of the study, 
and so forth. If we do so, we will likely 
fi nd that antimicrobial drug use is not 
a completely independent risk factor 
for the mentioned outcome, but a risk 
factor closely related to the availabil-
ity of the antibiotic-resistant microor-
ganism in the local environment or on 
our own hands.
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In Response: We appreciate 
the comments by Dr. Bellissimo-Ro-
drigues regarding our article analyzing 
risk factors for surveillance-culture 
positivity with extended-spectrum β-
lactamase (ESBL)–producing bacte-
ria (1). We agree with the author that 
patient-to-patient transmission is a 
potentially important causal factor in 
the emergence of resistance for ESBL-
producing bacteria as well as for other 
antimicrobial drug–resistant bacteria, 
such as vancomycin-resistant entero-
cocci, methicillin-resistant Staphy-
lococcus aureus, and drug-resistant 
Pseudomonas and Acinetobacter spp. 
For each of these resistant organ-
isms, a complicated interplay likely 
exists between the causal importance 
of antibiotic selective pressure and 
patient-to-patient transmission by 
healthcare workers (2–4). The relative 
importance of these 2 causal mecha-
nisms needs to be determined for 
each individual antimicrobial-resistant 
bacterium. The relative causal impor-
tance may be different for different 
outcomes: colonization on admission, 
colonization acquisition, and progres-
sion from colonization to infection. 
Understanding the relative importance 
for each of these outcomes is needed 
before determining whether infection 
control interventions or antimicrobial 
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